Microbicide research gets boost
The British government has given three South African organisations and researchers from five countries a multi-million rand grant to develop vaginal microbicides (a gel that can be used to prevent HIV transmission) over a five-year period.
The R272-million grant has been awarded to the Medical Research Council, the Africa Centre, Department of Obstetrics and Gynaecology at Wits University, and a group of international research collaborators in the UK, Uganda, Tanzania, Cameroon and Zambia.
The MRC’s Dr Gita Ramjee, says: “An effective microbicide – probably in a gel, foam sponge or a pessary – would be capable of blocking HIV and other sexually transmitted infections. Used prior to intercourse to block the development of infection in the vagina and cervix, it would significantly lower risk of HIV infection and be an important addition to efforts to combat HIV/AIDS.”
According to Ramjee, a microbicide “would offer women more choice and control, especially in situations where men do not, or will not use condoms. Microbicides are also likely to be cheap to produce and therefore affordable for women in poor countries.”
Two microbiocides, Dextrin sulphate and PRO 2000, are already in the process of being tested. PRO 2000 gel has received approval for clinical trials in the UK, USA and South Africa by the Food and Drug Administration in the US, and Dextrin sulphate has received approval by the Medicines Control Agency in the UK. – Health-e News Service.
Author
Kerry Cullinan is the Managing Editor at Health-e News Service. Follow her on Twitter @kerrycullinan11
Republish this article
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Unless otherwise noted, you can republish our articles for free under a Creative Commons license. Here’s what you need to know:
You have to credit Health-e News. In the byline, we prefer “Author Name, Publication.” At the top of the text of your story, include a line that reads: “This story was originally published by Health-e News.” You must link the word “Health-e News” to the original URL of the story.
You must include all of the links from our story, including our newsletter sign up link.
If you use canonical metadata, please use the Health-e News URL. For more information about canonical metadata, click here.
You can’t edit our material, except to reflect relative changes in time, location and editorial style. (For example, “yesterday” can be changed to “last week”)
You have no rights to sell, license, syndicate, or otherwise represent yourself as the authorized owner of our material to any third parties. This means that you cannot actively publish or submit our work for syndication to third party platforms or apps like Apple News or Google News. Health-e News understands that publishers cannot fully control when certain third parties automatically summarise or crawl content from publishers’ own sites.
You can’t republish our material wholesale, or automatically; you need to select stories to be republished individually.
If you share republished stories on social media, we’d appreciate being tagged in your posts. You can find us on Twitter @HealthENews, Instagram @healthenews, and Facebook Health-e News Service.
You can grab HTML code for our stories easily. Click on the Creative Commons logo on our stories. You’ll find it with the other share buttons.
If you have any other questions, contact info@health-e.org.za.
Microbicide research gets boost
by Kerry Cullinan, Health-e News
January 18, 2002